SCHEMBL2933705

SCHEMBL2933705

O=C(O)c1ccc(Nc2cncc(-c3cc4cc(F)ccc4[nH]3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 6/20 0.48
SLC22A12 Q96S37 6/20 0.48
KDM4E B2RXH2 1/20 0.43
PDPK1 O15530 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
APEX1 P27695 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
AURKA O14965 1/20 0.40
CYP1A1 P04798 2/20 0.39
GCGR P47871 1/20 0.39
MAPK14 Q16539 1/20 0.39
ULK1 O75385 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931673 0.89 MAP2K4 (0.43) XDHSLC22A12KDM4ELMNAHPGD
SCHEMBL27745032 0.85 PPARA (0.47) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL13515305 0.83 PYGL (0.42) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL2930138 0.83 MKNK2 (0.47)
SCHEMBL2927768 0.80 HRH4 (0.49) HPGD
Trifluoroacetic Acid SCHEMBL2931649 0.78 HRH4 (0.45)
SCHEMBL13515295 0.78 CCNA2 (0.41) KDM4ELMNAHPGDAURKAMAP2K4
SCHEMBL2934227 0.76 DYRK2 (0.45)
SCHEMBL2927033 0.76 GRM5 (0.49)
SCHEMBL1606684 0.74 CYP1A1 (0.54) KDM4EPDPK1ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
CN-101472912-A Pyridine and pyrazine derivatives as MNK kinase inhibitors BIOVITRUM AB PUBL (SE) 2009-07-01 CN disclosed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 XDH 729/4885SLC22A12 4444/4885KDM4E 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.